Search - tctmd.com

Displaying 201 - 220 of 464

Sort: Relevancy | Date

News Daily News

Smoker’s Paradox Debunked: Post-STEMI Outcomes Worse in Cigarette Smokers

Michael O'Riordan

April 15, 2020

Hope for these hard-to-treat patients: more than half saw ≥ 50% decrease at 24 weeks, regardless of LDL receptor function.

News Conference News ACC 2020

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Yael L. Maxwell

April 01, 2020

News Conference News ACC 2020

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

Todd Neale

March 28, 2020

News Daily News

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

Michael O'Riordan

March 13, 2020

News Opinion Editor's Corner

COVID-19 and the Heart: Insights From the Front Lines

Shelley Wood

March 12, 2020

News Daily News

LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure

Shelley Wood

March 10, 2020

News Daily News

Type 2 MI Linked to More CV Deaths, Even in Younger Patients

Shelley Wood

March 04, 2020

News Daily News

Poor Sleepers at Higher Risk of CVD, MESA Data Suggest

Caitlin E. Cox

March 04, 2020

News Daily News

Trials of New Cancer Drugs Failing to Address Potential CV Risks

Todd Neale

February 10, 2020

News Daily News

Revascularization After PCI or CABG Linked to Higher Mortality: EXCEL

Michael O'Riordan

January 17, 2020

News Daily News

Hypertension Starts Years Earlier in Women Than Men, Serial BP Shows

L.A. McKeown

January 17, 2020

News Daily News

Extreme Alcohol Intake Directly Damages the Heart, Study Confirms

Caitlin E. Cox

December 24, 2019

News Daily News

Higher Chili Pepper Consumption Linked to Fewer CVD Deaths

L.A. McKeown

December 17, 2019

News Daily News

FDA Approves Icosapent Ethyl for Reducing CVD Events

Michael O'Riordan

December 13, 2019

News Conference News AHA 2019

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

Todd Neale

November 18, 2019

Presentation AHA 2019

Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients With Elevated Triglycerides on Statin Therapy: The EVAPORATE Study

Presenter: Matthew Budoff

November 18, 2019

News Conference News AHA 2019

Inclisiran Slashes LDL in ASCVD Patients: ORION-10

Yael L. Maxwell

November 16, 2019

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Caitlin E. Cox

November 16, 2019

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Conference News AHA 2019

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

Shelley Wood

November 11, 2019

Advertisement

Smoker’s Paradox Debunked: Post-STEMI Outcomes Worse in Cigarette Smokers

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

COVID-19 and the Heart: Insights From the Front Lines

LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure

Type 2 MI Linked to More CV Deaths, Even in Younger Patients

Poor Sleepers at Higher Risk of CVD, MESA Data Suggest

Trials of New Cancer Drugs Failing to Address Potential CV Risks

Revascularization After PCI or CABG Linked to Higher Mortality: EXCEL

Hypertension Starts Years Earlier in Women Than Men, Serial BP Shows

Extreme Alcohol Intake Directly Damages the Heart, Study Confirms

Higher Chili Pepper Consumption Linked to Fewer CVD Deaths

FDA Approves Icosapent Ethyl for Reducing CVD Events

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients With Elevated Triglycerides on Statin Therapy: The EVAPORATE Study

Inclisiran Slashes LDL in ASCVD Patients: ORION-10

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content